(Q46866119)

25 December 2017

title

Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV. (English)

1 reference

25 December 2017

author name string

Bishnu P De

1

1 reference

25 December 2017

Neil R Hackett

2

1 reference

25 December 2017

Ronald G Crystal

3

1 reference

25 December 2017

Julie L Boyer

4

1 reference

25 December 2017

publication date

4 December 2007

1 reference

25 December 2017

published in

Molecular Therapy

1 reference

25 December 2017

volume

16

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

203-209

1 reference

25 December 2017

Adeno-associated virus vectors for therapeutic gene transfer

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Anthrax as a biological weapon, 2002: updated recommendations for management

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Airborne infection with Bacillus anthracis--from mills to mail

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

1 reference

7 January 2021

Identification of the cellular receptor for anthrax toxin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Manipulation of host signalling pathways by anthrax toxins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Development of novel vaccines against anthrax in man.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

The effectiveness and safety of vaccines against human anthrax: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

In vitro correlate of immunity in a rabbit model of inhalational anthrax

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Passive transfer of protection against Bacillus anthracis infection in a murine model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Human antibodies from immunized donors are protective against anthrax toxin in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Baculovirus expression of a human G2-specific, neutralizing IgG monoclonal antibody to Puumala virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

High In Vivo Production of a Model Monoclonal Antibody on Adenoviral Gene Transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Stable antibody expression at therapeutic levels using the 2A peptide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Cap-independent translation of poliovirus mRNA is conferred by sequence elements within the 5' noncoding region

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300344

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300344

1 reference

25 December 2017

PubMed ID

18059375

1 reference

25 December 2017